Agios axes 100-plus R&D roles while awaiting FDA decision - BioSpace
BioSpace · Nov 6, 2:23 PM
Agios Pharmaceuticals: Q3 Earnings Snapshot - Yahoo Finance
Yahoo Finance · Nov 5, 11:40 AM
Market reactionShares fell 12% on Nov 5.
Agios is a commercial-stage company whose drug mitapivat is approved for thalassemia and is under FDA review for sickle cell disease.
Mitapivat is approved for thalassemia in the US, EU, Saudi Arabia and UAE, and worldwide sales reached $44.7 million in Q2 2026. In sickle cell disease, Phase 3 RISE UP improved hemoglobin but missed statistical significance on pain crises, so FDA's November 1 accelerated-approval decision is the key test. If approved, the confirmatory REIGNITE trial must show that mitapivat reduces transfusion burden.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves mitapivat in sickle cell disease
Does FDA grant accelerated approval for mitapivat in sickle cell disease?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Mitapivat's November 1 sickle cell decision follows a hemoglobin win and a pain-crisis miss
Two approvals in thalassemia anchor the commercial story, but a sickle cell sNDA on single-arm accelerated-approval data is the make-or-break next step
Approved in thalassemia with sickle cell sNDA accepted, mitapivat's commercial scale depends on whether accelerated approval converts to full label
Mitapivat's sickle cell sNDA under accelerated approval tests whether a second major label can transform Agios into a durable rare hematology franchise
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Mitapivat
Disease areas: Blood cancers, Blood disorders, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.